<DOC>
	<DOCNO>NCT03051256</DOCNO>
	<brief_summary>This Phase 2a , multicenter , randomize , double-blind , placebo control 3 arm study assess safety tolerability multiple oral dos REL-1017 25 mg 50 mg adjunctive therapy treatment patient diagnose major depressive disorder ( MDD ) . The patient adult MDD diagnose current MDE experience inadequate response 1 3 course treatment antidepressant medication . This population provide opportunity compare safety efficacy effect treatment approve antidepressant conjunction REL-1017 versus effect antidepressant alone . This study include in-patient out-patient period .</brief_summary>
	<brief_title>Safety , Tolerability , PK , Symptom Response REL-1017 ( d-Methadone ) Major Depressive Disorder</brief_title>
	<detailed_description>Currently available medication proven useful treatment depression , also limitations include low response rate , significant number treatment resistant patient , time-lag response , emphasize major unmet need efficacious faster-acting antidepressant . Recent study demonstrate ketamine , non-competitive glutamate-N-methyl-D-Aspartate ( NMDA ) receptor antagonist , produce rapid onset ( 2 hour ) long-lasting ( 7 day ) antidepressant action treatment resistant patient . This rapid action , mechanism completely different typical monoamine reuptake inhibitor , represent significant finding field depression . Racemic methadone , 50/50 combination d-methadone l-methadone , widespread use decade study extensively . Methadone currently approve use management severe pain , detoxification treatment opioid addiction , maintenance treatment opioid addiction . The result study evaluate receptor bind profile racemic methadone stereoisomers suggest d-methadone essentially contribute opioid effect racemic methadone 10 time low affinity mu1 , mu2 , delta opioid receptor compare l-methadone . Racemic methadone d- l isomer exhibit similar affinity non-competitive bind site NMDA receptor non-competitive NMDA receptor antagonist . In forced swim test , rodent behavioral model antidepressant activity , ketamine d-methadone dos test significantly decrease immobility rat compare vehicle suggest antidepressant like activity . Neither drug increase spontaneous locomotor activity . Relmada conduct 2 clinical study identify dose level REL-1017 ( d-methadone ) little opioid effect expect possess NMDA antagonistic property evaluation oral REL-1017 treatment MDD neuropathic pain condition . Initial Phase 1 single ascend dose multiple ascend dose clinical study REL-1017 design evaluate safety tolerance pure methadone isomer healthy opioid-naïve subject identify safe potentially effective dose range population . These study show REL-1017 safe well-tolerated single oral dos 150 mg ( maximum tolerate dose ) 75 mg administer daily 10 day healthy opioid-naïve subject . The pre-clinical previous clinical experience REL-1017 ( d-methadone ) provide basis initiation present study , extend evaluation safety , tolerability , PK REL-1017 2 dos repeat administration depress patient . Since REL-1017 propose use adjunctive therapy treatment patient diagnose major depressive disorder ( MDD ) , patient male adult MDD diagnose current depressive episode experience inadequate response 1 3 course treatment antidepressant medication . Based safety data Protocol REL-1017-111 , single dose 5 mg , 20 mg , 60 mg , 100 mg , 150 mg REL-1017 placebo well tolerate . The result Protocol REL-1017-112 evaluate 10 day dose 25 mg , 50 mg 75 mg REL-1017 placebo , impact safety observe . In spite confirm dose proportionality , comparison concentration exposure 50 mg 75 mg REL-1017 treatment group demonstrate slight difference . Consequently , 25 mg 50 mg dos choose administration Protocol REL-1017-202 single daily dos period 7 day . Thus , single isomer racemic methadone , d-methadone show posse NMDA antagonist property virtually opioid activity ketamine-like toxicity expect therapeutic dos . In study , adult male patient MDD diagnose current MDE experience inadequate response 1 3 course treatment antidepressant medication randomize study drug 1:1:1 ratio . Approximately 15 patient receive REL-1017 25 mg , REL-1017 50 mg , placebo daily 7 day . Endpoints include assessment safety , tolerability , efficacy pharmacokinetics REL-1017 . Patients require stay clinic 10 day follow outpatient 12 additional day .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<mesh_term>Excitatory Amino Acid Antagonists</mesh_term>
	<criteria>Males 18 65 year age , inclusive . Diagnosed recurrent major depressive disorder define Diagnostic Statistical Manual , Fifth Edition ( DSM5 ) . Diagnosed current major depressive episode ( MDE ) . Treated adequate dosage selective serotonin reuptake inhibitor ( SSRI ) , serotonin norepinephrine reuptake inhibitor ( SNRI ) , bupropion current MDE . Have experience inadequate response 1 3 course treatment antidepressant medication current episode . Able meet study requirement , include confined/inpatient portion study , adherence approve antidepressant therapy ( ADT ) study drug regimen , completion assessment schedule visit . Additional criterion apply . Chronic use prescribe opioids ( i.e. , &gt; 120 day 6month period ) 6 month prior Screening recreational use opioids . History allergy hypersensitivity methadone relate drug ( e.g. , opioids ) . History presence condition opioid contraindicate ( e.g. , significant respiratory depression , acute severe bronchial asthma hypercarbia , bronchitis , has/is suspect paralytic ileus ) . Use antipsychotic , anticonvulsant , mood stabilizer , regardless indication , within 6 month prior Screening . Any current primary psychiatric disorder , define condition primary focus distress and/or treatment , MDD . Any lifetime history bipolar I II disorder , persistent depressive disorder , psychotic disorder , posttraumatic stress disorder , borderline personality disorder , antisocial personality disorder , obsessive compulsive disorder , eat disorder , intellectual disability , pervasive developmental disorder . Patients significant risk suicide . Patients take fluvoxamine St. John 's Wort . Additional criterion apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>REL-1017</keyword>
	<keyword>d-Methadone</keyword>
	<keyword>Methadone</keyword>
	<keyword>Depression</keyword>
	<keyword>Refractory Depression</keyword>
	<keyword>Antidepressant</keyword>
	<keyword>Adjunctive Treatment</keyword>
	<keyword>NMDA Receptor Antagonist</keyword>
	<keyword>Excitatory Amino Acid Antagonist</keyword>
	<keyword>Glutamate Antagonist</keyword>
</DOC>